Skip to main content
新赣江 logo

新赣江 — Investor Relations & Filings

Ticker · 920367 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 389 across all filing types
Latest filing 2026-01-12 Regulatory Filings
Country CN China
Listing Beijing Stock Exchange 920367

About 新赣江

http://www.xgjyy.com/

Jiangxi Xinganjiang Pharmaceutical Co., Ltd. specializes in the research, development, production, and distribution of a diverse range of pharmaceutical products. The company's portfolio encompasses chemical active pharmaceutical ingredients (APIs), chemical drug preparations, and traditional Chinese medicine (TCM) formulations. Its core product offerings target therapeutic areas such as cardiovascular and cerebrovascular health, digestive system disorders, and nutritional supplementation. Key products include Ginkgo Biloba extract, Vitamin C, and various gastrointestinal medications. By maintaining an integrated value chain that spans from raw material synthesis to finished dosage forms, the company ensures quality control and supply chain efficiency. It focuses on delivering high-quality healthcare solutions through continuous innovation in pharmaceutical manufacturing and formulation technology.

Recent filings

Filing Released Lang Actions
股票交易异常波动公告
Regulatory Filings Classification · 95% confidence The document is a public announcement regarding abnormal stock price fluctuations and related disclosures by the company. It includes details about stock price changes, verification of insider trading or undisclosed material information, and risk warnings to investors. The document does not contain financial statements, audit information, or detailed financial results. It is a regulatory announcement about stock trading activity and compliance with stock exchange rules, typical of a Regulatory Filings (RNS) category. The document length is short (1164 characters), and it is not an announcement of a report publication but a standalone disclosure. Therefore, the appropriate classification is Regulatory Filings (RNS).
2026-01-12 Chinese
关于预计2026年日常性关联交易的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the company's expected related party transactions for the year 2026. It includes details about the nature and estimated amounts of these transactions, the related parties involved, the decision-making and approval process by the board and committees, pricing policies, and the impact on the company. It also contains statements from the sponsor institution confirming compliance with regulatory requirements. The document is not a full financial report, audit report, or earnings release, nor is it a voting result or management change announcement. It is a regulatory announcement about related party transactions, which fits best under Regulatory Filings (RNS) as it does not fit other more specific categories and is a compliance disclosure.
2026-01-11 Chinese
财通证券股份有限公司关于江西新赣江药业股份有限公司预计2026年日常性关联交易的核查意见
Regulatory Filings Classification · 95% confidence The document is a detailed opinion from a sponsoring securities company regarding the expected related party transactions for the year 2026 of Jiangxi Xinganjiang Pharmaceutical Co., Ltd. It includes transaction categories, amounts, related parties, pricing policies, fairness, decision-making procedures, and the sponsor's verification opinion. The document references regulatory rules related to securities issuance and listing on the Beijing Stock Exchange and includes board meeting resolutions and voting results. It is not a full financial report, audit report, or earnings release, but rather a regulatory compliance and verification document related to related party transactions. The document length is 3632 characters, which is relatively short but contains substantive content rather than just an announcement. It does not fit into categories like Annual Report, Interim Report, or Earnings Release. It is a regulatory filing related to compliance and disclosure of related party transactions, which aligns best with the Regulatory Filings (RNS) category as a fallback for miscellaneous regulatory compliance documents that do not fit other categories.
2026-01-11 Chinese
关于拟注销二级子公司的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the proposed cancellation (注销) of a secondary subsidiary company, including details about the subsidiary, the board meeting resolution, and the impact on the company. It is a corporate announcement about a structural change rather than a financial report or detailed management discussion. The document length is short (1155 characters), and it does not contain financial statements or detailed financial analysis. It is not a report publication announcement since it contains substantive content about the cancellation decision. This fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous corporate announcements that do not fit other specific categories such as MANG (management changes) or CAP (capital changes).
2026-01-11 Chinese
第三届董事会第十五次会议决议公告
Board/Management Information Classification · 95% confidence The document is an announcement of resolutions passed at the fifteenth meeting of the third board of directors of Jiangxi Xinganjiang Pharmaceutical Co., Ltd. It details meeting attendance, agenda items, voting results, and related disclosures. The content focuses on board decisions regarding related party transactions and subsidiary deregistration, with no financial statements or detailed financial analysis included. The document is a formal disclosure of board meeting outcomes, which fits the category of Board/Management Information (MANG). The document length is short and it is not a full report but an announcement of board decisions, so it is not an Annual Report or Interim Report. Therefore, the classification is MANG with high confidence.
2026-01-11 Chinese
持股5%以上股东权益变动触及5%整倍数的提示性公告
Major Shareholding Notification Classification · 100% confidence The document is a public announcement regarding changes in shareholding percentages by shareholders holding more than 5% of the company's shares. It details the reduction in shareholdings by specific shareholders, the impact on total shareholding percentages, and confirms compliance with relevant securities laws. The document does not contain financial statements, management discussion, or audit information. It is a notification of a major shareholding change, specifically a shareholding notification crossing a 5% threshold. Therefore, it fits the category of Major Shareholding Notification (MRQ). The document length is 2412 characters, which is consistent with a typical shareholding notification rather than a full report or announcement of a report publication.
2026-01-11 Chinese

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.